Literature DB >> 11824810

Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry.

Ute Hofmann1, Monika Seiler, Siegfried Drescher, Martin F Fromm.   

Abstract

A sensitive method was developed to determine fexofenadine in human plasma and urine by HPLC-electrospray mass spectrometry with MDL 026042 as internal standard. Extraction was carried out on C18 solid-phase extraction cartridges. The mobile phases used for HPLC were: (A) 12 mM ammonium acetate in water and (B) acetonitrile. Chromatographic separation was achieved on a LUNA CN column (10 cm x 2.0 mm I.D., particle size 3 microm) using a linear gradient from 40% B to 60% B in 10 min. The mass spectrometer was operated in the selected ion monitoring mode using the respective MH+ ions, m/z 502.3 for fexofenadine and m/z 530.3 for the internal standard. The limit of quantification achieved with this method was 0.5 ng/ml in plasma and 1.0 ng in 50 microl of urine. The method described was successfully applied to the determination of fexofenadine in human plasma and urine in pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11824810     DOI: 10.1016/s0378-4347(01)00468-6

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Quantification of the transporter substrate fexofenadine in cell lysates by liquid chromatography/tandem mass spectrometry.

Authors:  Colleen A Flynn; Yazen Alnouti; Gregory A Reed
Journal:  Rapid Commun Mass Spectrom       Date:  2011-08-30       Impact factor: 2.419

2.  MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.

Authors:  Siegfried Drescher; Elke Schaeffeler; Monika Hitzl; Ute Hofmann; Matthias Schwab; Ulrich Brinkmann; Michel Eichelbaum; Martin F Fromm
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

3.  Validation and application of a liquid chromatography-tandem mass spectrometric method for quantification of the drug transport probe fexofenadine in human plasma using 96-well filter plates.

Authors:  Melonie L Stanton; Melanie S Joy; Reginald F Frye
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-12-24       Impact factor: 3.205

4.  Identification and Characterization of an Oxidative Degradation Product of Fexofenadine, Development and Validation of a Stability-Indicating RP-UPLC Method for the Estimation of Process Related Impurities and Degradation Products of Fexofenadine in Pharmaceutical Formulations.

Authors:  Bhupendrasinh Vaghela; Surendra Singh Rao; Annarapu Malleshwar Reddy; Panuganti Venkatesh; Navneet Kumar
Journal:  Sci Pharm       Date:  2012-01-21

5.  Does Ethnic Variability Exist in the Systemic Exposures of OATP1A2 Substrates-Fexofenadine in Taiwanese?

Authors:  Y A Chen; C H Juan; K Y Hsu
Journal:  Indian J Pharm Sci       Date:  2015 Sep-Oct       Impact factor: 0.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.